Donghui Ma, Ph.D., CEO of DIMA discusses the use of the company’s single B technology to develop lead antibody molecules on GPCR targets in this interactive webinar. Register now to learn more about DIMA’s discovery platforms for therapeutic lead antibodies, including DiMPro, DimAb, and DiLibrary; CAR T cell therapy development; and the company’s on-shelf lead antibody molecules.